Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients

ConclusionTo our knowledge, this is the largest population PK analysis of escitalopram and sertraline in pediatric patients. Significant PK variability for both medications was observed and was largely explained by CYP2C19 phenotype. Slower CYP2C19 metabolizers taking escitalopram or sertraline may benefit from dose reductions given increased exposure.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research